Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Universal American Announces New Medicare Part D Benefit Making LIPITOR® and CRESTOR® Available for Low or No Copay(1)

Plans can save enrollees an estimated $230-$300 in 2011(2) on two popular cholesterol-lowering drugs through a network of 64,000 pharmacies nationwide


News provided by

Universal American

Oct 28, 2010, 09:00 ET

Share this article

Share toX

Share this article

Share toX

RYE BROOK, N.Y., Oct. 28 /PRNewswire/ -- Universal American (NYSE: UAM), the nation's second largest Medicare Part D sponsor(3), has partnered with the makers of LIPITOR and CRESTOR to provide broad and affordable access to these cholesterol-lowering prescription drugs. Effective January 1, 2011, all members of Universal American's Medicare Part D Prescription drug plans, Community CCRx(SM) PDP, as well as all members of its Medicare Advantage Prescription Drug (MA-PD) plans can purchase these popular drugs for low or no monthly copayments(4) through the company's nationwide network of 64,000 pharmacies, including independent pharmacies, regional chain stores, and major retail drug chains.

"Heart disease is a major health issue for older Americans," said John Wardle, President of Universal American's Medicare Prescription Drug Plan business. "While all Medicare Part D Prescription Drug plans cover statins, most of these plans require substantial copays for the most popular brand-name statins. These drugs can be expensive, especially for older adults on a fixed income. By forming partnerships with Pfizer and AstraZeneca, the makers of LIPITOR and CRESTOR, Universal American members can save $230 to $300(5) on these cholesterol-lowering drugs in one year."

Why These Medications?

Cardiovascular disease is the number one cause of death for people over the age of 75,(6) and high cholesterol plays a major role in developing this disease.(7) According to the Centers for Disease Control and Prevention,  about one in every six adults have high cholesterol(8). Over 33.5 million older Americans currently take a statin drug or should be taking one(9) making it the most prescribed drug class in the U.S.(10), with LIPITOR and CRESTOR being two of the most popular brands.(11)

"For two out of three people,(12) diet and exercise alone are not enough to lower cholesterol," said Nelson Fernandez, M.D., Senior Medical Director of Universal American. "Drug therapy like statins, may help reduce the amount of bad cholesterol and ultimately lower the incidence of stroke or heart attack."

Michael A. Suesserman, Vice President, U.S. Corporate and Government Customers, Pfizer said, "We at Pfizer strive to provide patients with access to safe, effective and affordable medicines. To ensure we can continue to deliver on our commitments to patients, we welcome opportunities like this partnership with Universal American to allow greater access to medicines like Lipitor."

Universal American is committed to A Healthy Collaboration(SM), a pledge it shares with physicians, pharmacists and other healthcare providers to work together to improve members' health. It means encouraging members to see their doctors and fill their prescriptions regularly because it will help them prevent illness and manage disease, as well as drive down costs so they can save money and stay healthy. Joining with Pfizer and AstraZeneca (makers of LIPITOR and CRESTOR, respectively) to make these two drugs more affordable is another example of how Universal American is making it easier for those with Medicare, including seniors and people with disabilities, to improve and protect their health.

As healthcare evolves, people with Medicare will have questions about their health coverage. Universal American is listening to these concerns and providing innovative approaches that bring members more options that control their healthcare costs. For more information about Community CCRx and Universal American, visit www.UniversalAmerican.com.  

About Universal American

Universal American (NYSE: UAM), through our family of healthcare companies, provides health benefits to nearly two million people with Medicare every day.* We are dedicated to working collaboratively with healthcare professionals in order to improve the health and well-being of our members. 

*2009 Annual Report, April 2010; available at www.UniversalAmerican.com

Notes:  

Today's Options PPO®, Today's Options® PFFS, Today's Options® HMO, TexanPlus® HMO, Generations Healthcare HMO, Today's Health® HMO, Tribute HMO SNP, and Fresenius Health Partners PPO SNP are Medicare-approved PPO, PFFS and HMO plans and Community CCRx(SM) PDP is a federally qualified Medicare Contracting Prescription Drug Plan offered by the following organizations that contract with the Federal government:  The Pyramid Life Insurance Company; SelectCare Health Plans (d/b/a TexasFirst Health Plans® and d/b/a Today's Options of Indiana, in Texas and Indiana, respectively); SelectCare of Oklahoma, Inc.; GlobalHealth, Inc.; SelectCare of Texas, L.L.C.; American Progressive Life & Health Insurance Company of New York; and Pennsylvania Life Insurance Company, members of the Universal American family of companies; and Abri Health Plan Inc. (administered by a member of the Universal American family of companies).

Prices may vary for Medicare Advantage Prescription Drug plans, based on region. Benefits, formulary, pharmacy network, premium and/or copayments/coinsurance may change on January 1, 2012. The benefit information provided herein is a brief summary, not a comprehensive description of benefits. For more information, contact the plan. Limitations, copayments and restrictions apply. You must continue to pay your Part B premium.

You may be able to get Extra Help to pay for your prescription drug premiums and costs. To see if you qualify for extra help, call 1-800-MEDICARE (1-800-633-4227). TTY users should call 1-877-486-2048, 24 hours a day/7 days a week. Call the Social Security Office at 1-800-772-1213 between 7:00 a.m. and 7:00 p.m., Monday through Friday. TTY users should call 1-800-325-0778 or your State Medicaid Office.

This information is available in a different format, including Spanish. Please call Customer Service at the number listed (above/below) if you need plan information in another format or language. Esta informacion esta disponible en diferentes formatos, incluyendo el espanol. Por favor llame a Servicios al Cliente al numero indicado arriba si necesita informacion del plan en otro formato u idioma.

We have formed a network of pharmacies. To receive plan prescription drug benefits, you must use a network pharmacy, except in non-routine circumstances, and quantity limitations and restrictions may apply.

(1) Effective January 1, 2011, this low copay is for each 30-day supply during the Initial Coverage Stage. (2) For our current members [who take Lipitor or Crestor], we estimate the savings to be between $230 and $300 per year; we believe that similar savings will be achieved in out-of-pocket costs as compared to other Part D plans that have higher co-pays for these medications. Savings estimate is based on a comparison between annual average projected costs for a 30-day supply for a member for the 2011 benefit year versus 2010 benefit year.  Actual savings may vary.  (3)Source: CMS.gov; April 2010. (4) Effective January 1, 2011, this low copay is for each 30-day supply during the Initial Coverage Stage. (5) For our current members [who take Lipitor or Crestor], we estimate the savings to be between $230 and $300 per year; we believe that similar savings will be achieved in out-of-pocket costs as compared to other Part D plans that have higher co-pays for these medications. Savings estimate is based on a comparison between annual average projected costs for a 30-day supply for a member for the 2011 benefit year versus 2010 benefit year.  Actual savings may vary. (6) Source: American Heart Association, http://www.americanheart.org/downloadable/heart/1236979840760CAUSES_DEATH.pdf (7)Source: National Heart, Lung and Blood Institute (NHLBI), http://www.nhlbi.nih.gov/health/public/heart/chol/wyntk.htm Copyright 2001 - 2005 © NIH Publication No. 05-3290 (8) Source: Centers for Disease Control and Prevention (CDC).  National Center for Chronic Disease Prevention and Health Promotion, Division for Heart Disease and Stroke Prevention, http://www.cdc.gov/cholesterol. (August 2010)  (9)Source: National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, [1999-2004]. (10)Source: http://www.cdc.gov/nchs/data/databriefs/db42.pdf NCHS Data Brief, No. 42, 9/2010. (11) Source: Verispan, LLC - Top 200 TRx products-65+(Aug 10) (12) Source: Pfizer. (2010). Lipitor official site - lipitor.com. Retrieved from http://www.lipitor.com.

Media Contact:

Jenn Riggle

For Universal American

757-640-1982 ext. 25

[email protected]

SOURCE Universal American

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2026 Cision US Inc.